Dechra Pharmaceuticals PLC Appointment of Chief Financial Officer (5470R)

TIDMDPH

RNS Number : 5470R

Dechra Pharmaceuticals PLC

30 October 2019

30 October 2019

Dechra(R) Pharmaceuticals PLC

(Dechra, Company or the Group)

Board Change

Appointment of Chief Financial Officer

Dechra is pleased to announce that Paul Sandland, acting Chief Financial Officer since April this year, has been appointed as an Executive Director and permanent Chief Financial Officer of the Company with immediate effect.

Paul qualified as a Chartered Certified Accountant with KPMG in 2005 and joined Dechra in 2010 as Group Financial Controller. Between 2012 and 2013 Paul was Acting CFO prior to becoming the Group's Dechra Veterinary Products EU finance director, a position he held until April this year.

Commenting on the appointment Tony Rice, Chairman, said:

"I am delighted to confirm Paul's appointment as Dechra's permanent CFO. Paul has proven to be an excellent acting CFO and, over a much longer period, has clearly demonstrated a strong practical understanding of all parts of the Group and its needs, as well as an independence of mind and strong technical, strategic and commercial skills. The Company followed a rigorous process before appointing Paul. He has been a core part of the Dechra leadership team over the last ten years."

Paul Sandland, Chief Financial Officer added:

"I am delighted to take on the CFO role on a permanent basis. Dechra is a wonderful, well invested Company with global brands and significant growth opportunities ahead of it. Whilst I have been privileged to be part of the development of Dechra over the last ten years, I am confident that Dechra continues to have enormous potential and, working alongside the talented pool of people we have around the business at all levels, I look forward to helping unlock that potential."

Paul Sandland currently has a beneficial interest in the Company totalling 5,069 shares which represents 0.005% of the current issued share capital.

There are no other disclosures required in respect of this appointment pursuant to Listing Rule 9.6.13R.

 
 Enquiries to: 
 TooleyStreet Communications Ltd 
 Fiona Tooley, Director 
  Mobile: [phone] 
  e-mail: [e-mail] 
 Dechra Pharmaceuticals PLC 
 Melanie Hall, Company Secretary 
 Office: [phone] 
 e-mail: [e-mail] 
 

About Dechra

Dechra is a global veterinary pharmaceuticals and relates products business. Our expertise is in the development, manufacture and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.

For more information please visit: www.dechra.com

Stock Code: Full Listing (Pharmaceuticals): DPH

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

BOALFFIVIALAFIA

(END) Dow Jones Newswires

October 30, 2019 03:00 ET (07:00 GMT)